Literature DB >> 7995987

Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of gram-negative sepsis: role of bactericidal properties.

W S Ammons1, F R Kohn, A H Kung.   

Abstract

Effects of an N-terminal fragment of bactericidal/permeability increasing protein (rBPI21) on bacterial infections were determined. Intravenous (i.v.) rBPI21 increased survival and reduced bacteremia in rats after an iv injection of Escherichia coli O7:K1 bacteria. rBPI21 inhibited the rise in tumor necrosis factor-alpha resulting from challenge with 2 strains of E. coli. Intraperitoneal (ip) injection of rBPI21 increased survival of mice after ip injection of E. coli O7:K1 and Pseudomonas aeruginosa and reduced bacteria in peritoneal lavage fluid and blood and inhibited cytokine production in response to E. coli. rBPI21 alone did not protect mice challenged with E. coli O111:B4 but was protective and reduced bacterial counts when administered in combination with the antibiotic cefamandole. The data show that protection with rBPI21 is associated with reductions in bacterial counts and is enhanced by antibiotics. Bactericidal activity, in addition to antiendotoxin activity, is involved in the efficacy of rBPI21 in models of gram-negative infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995987     DOI: 10.1093/infdis/170.6.1473

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.

Authors:  A A Khan; L H Lambert; J S Remington; F G Araujo
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.

Authors:  C Urban; N Mariano; J J Rahal; E Tay; C Ponio; T Koprivnjak; J Weiss
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  Effect of anticoagulants on binding and neutralization of lipopolysaccharide by the peptide immunoglobulin conjugate CAP18(106-138)-immunoglobulin G in whole blood.

Authors:  M Ogata; M F Fletcher; M Kloczewiak; P M Loiselle; E M Zanzot; M W Vermeulen; H S Warren
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  A Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases.

Authors:  M G Vallespi; L A Glaria; O Reyes; H E Garay; J Ferrero; M J Araña
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

5.  Protective effect of bactericidal/permeability-increasing protein (rBPI21) in baboon sepsis is related to its antibacterial, not antiendotoxin, properties.

Authors:  G Schlag; H Redl; J Davies; P Scannon
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

6.  Lipopolysaccharide-induced E-selectin expression requires continuous presence of LPS and is inhibited by bactericidal/permeability-increasing protein.

Authors:  K Huang; D M Fishwild; H M Wu; R L Dedrick
Journal:  Inflammation       Date:  1995-06       Impact factor: 4.092

Review 7.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

8.  Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis.

Authors:  Y Lin; W J Leach; W S Ammons
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 9.  Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.

Authors:  María Escobar-Salom; Gabriel Torrens; Elena Jordana-Lluch; Antonio Oliver; Carlos Juan
Journal:  Biol Rev Camb Philos Soc       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.